Effect of severe renal impairment on the pharmacokinetics of brigatinib

Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, targets activated, mutant forms of ALK and overcomes mechanisms of resistance to the ALK inhibitors crizotinib, ceritinib, and alectinib. Brigatinib is approved in multiple countries for treatment of patients with A...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Kerstein, David, Tugnait, Meera, Narasimhan, Narayana, Marbury, Thomas C., Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426299/
https://www.ncbi.nlm.nih.gov/pubmed/33742299
http://dx.doi.org/10.1007/s10637-021-01095-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426299/
https://www.ncbi.nlm.nih.gov/pubmed/33742299
http://dx.doi.org/10.1007/s10637-021-01095-5

Ejemplares similares